ArticleCroatian medical journal2024

Could choosing risdiplam instead of nusinersen in the treatment of type 1 spinal muscular atrophy be a huge cost-minimization opportunity?

Andrej Belančić et al.PubMed ↗Full text ↗

No numbers read from the abstract.